Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248583 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CES2TSHREPHX2THRB | |
| SCHEMBL4182541 | 0.98 | ALDH1A1 (0.36) | ALDH1A1CES2TSHREPHX2THRB | |
| SCHEMBL2418120 | 0.93 | — | — | |
| SCHEMBL9176896 | 0.91 | ALDH1A1 (0.35) | ALDH1A1TSHRTHRBKDM4EPOLB | |
| SCHEMBL27905163 | 0.85 | MEN1 (0.42) | ALDH1A1CES2TSHRTHRBMEN1 | |
| SCHEMBL7249902 | 0.84 | MEN1 (0.45) | ALDH1A1CES2TSHRTHRBMEN1 | |
| SCHEMBL4396265 | 0.84 | MEN1 (0.50) | ALDH1A1CES2TSHRTHRBMEN1 | |
| SCHEMBL5428007 | 0.84 | HTT (0.40) | ALDH1A1CES2TSHREPHX2THRB | |
| SCHEMBL7252399 | 0.84 | MEN1 (0.45) | ALDH1A1CES2TSHRTHRBMEN1 | |
| SCHEMBL7254836 | 0.84 | HTT (0.40) | ALDH1A1CES2TSHREPHX2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0813525-B9 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6686364-B2 | 4-HYDROXY-3-((3,5-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-0813525-B1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6602825-B1 | Cyclization of an isocyanate with a thiourea and carbonic acid | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-05 | — | — | US | disclosed |
| US-6479485-B2 | 4-HYDROXY-3-((3,4-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; INHIBITION OF BLOOD COAGGULATION FACTOR XA | BERLEX LABORATORIES, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6465459-B2 | INHIBIT THE ENZYME, FACTOR XA | BERLEX LABORATORIES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-21 | — | — | US | disclosed |
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-14 | — | — | US | disclosed |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-07 | — | — | US | disclosed |
| US-6350746-B1 | FACTOR XA ENZYME INHIBITORS | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
| US-5889005-A | Benzamidine derivatives and their use for treating thrombotic diseases | BERLEX LABORATORIES, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5883100-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5877181-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0813525-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5691364-A | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1996028427-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-5104888-A | Anticholesterol or antidiabetic agents | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0207581-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND USE | SANKYO COMPANY LIMITED (JP) | 1990-09-12 | — | — | EP | disclosed |
| EP-0207581-A2 | Thiazolidine derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | ALDH1A1 1000/4885CES2 581/4885TSHR 3998/4885 |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | ALDH1A1 1000/4885CES2 581/4885TSHR 3998/4885 |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | ALDH1A1 1036/4885CES2 607/4885TSHR 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.